Musa D Marimani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5270990/publications.pdf

Version: 2024-02-01

1307594 1199594 13 208 7 12 citations g-index h-index papers 13 13 13 322 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Carvacrol modulates the expression and activity of antioxidant enzymes in Candida auris. Research in Microbiology, 2022, 173, 103916.	2.1	6
2	Modulation of antioxidant defence system in response to berberine in <scp><i>Candida albicans</i></scp> . Yeast, 2021, 38, 157-169.	1.7	12
3	Citral and its derivatives inhibit quorum sensing and biofilm formation in Chromobacterium violaceum. Archives of Microbiology, 2021, 203, 1451-1459.	2.2	13
4	Tolerance of Listeria monocytogenes to biocides used in food processing environments. Food Microbiology, 2021, 97, 103758.	4.2	57
5	Examining the levels of acetylation, DNA methylation and phosphorylation in HIV-1 positive and multidrug-resistant TB-HIV patients. Journal of Global Antimicrobial Resistance, 2020, 23, 232-242.	2.2	4
6	<i>Lactobacillus rhamnosus</i> cell-free extract targets virulence and antifungal drug resistance in <i>Candida albicans</i> Canadian Journal of Microbiology, 2020, 66, 733-747.	1.7	4
7	Distinct epigenetic regulation in patients with multidrug-resistant TB-HIV co-infection and uninfected individuals. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2020, 821, 111724.	1.0	0
8	The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection. Tuberculosis, 2018, 113, 200-214.	1.9	46
9	Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs. Journal of Controlled Release, 2015, 209, 198-206.	9.9	22
10	Use of Guanidinopropyl-Modified siRNAs to Silence Gene Expression. Methods in Molecular Biology, 2015, 1218, 217-249.	0.9	1
11	Inhibition of hepatitis B virus replication in cultured cells and in vivo using 2′-O-guanidinopropyl modified siRNAs. Bioorganic and Medicinal Chemistry, 2013, 21, 6145-6155.	3.0	19
12	Recent advances in developing nucleic acid-based HBV therapy. Future Microbiology, 2013, 8, 1489-1504.	2.0	6
13	Synthesis of 2′-O-guanidinopropyl-modified nucleoside phosphoramidites and their incorporation into siRNAs targeting hepatitis B virus. Bioorganic and Medicinal Chemistry, 2012, 20, 1594-1606.	3.0	18